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ABSTRACT A clinical decision report appraising Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs 
without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a 
randomized clinical trial. JAMA. 2020;323(6):527–537. https://doi.org/10.1001/jama.2020.0103 for a patient with multiple 
comorbidities including heart failure, severe aortic regurgitation, aortic aneurysm and intellectual disability being treated for MRSA 
bacteremia who is intubated in the ICU. 
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Clinical Context 
Dominic Edwards (Pseudonym) is a 34-year-old man with developmental delay and a history of heart failure with 
reduced ejection fraction (EF of 30%), recurrent pleural effusions, 7.4 cm ascending aortic aneurysm, severe aortic 
regurgitation, and restrictive lung disease secondary to severe scoliosis, with nighttime BiPAP dependency. He was 
brought to the ED by his mother, his primary caregiver, after she thought he “wasn’t doing well and was drowsy.” 
He had struggled to use his BiPAP for the last two nights. He was found to be severely acidotic and was 
subsequently intubated in the MICU. 
On hospital day five, Mr. Edwards spiked a fever of 38.1°C. Blood cultures grew methicillin resistant Staphylococcal 
aureus (MRSA), and respiratory culture showed MRSA and Pseudomonas aeruginosa. The Infectious Disease 
service was consulted. At bedside, Mr. Edwards was intubated and diaphoretic, but still arousable and answering 
questions by nodding. With assistance from his mother, we discussed our plans. Mrs. Edwards stated that Dominic 
“just wasn’t himself,” and she “just wanted her son back.” As she is his primary caregiver, his current 
hospitalization was taxing on her, as she had other children at home in her care. He had several prior 
hospitalizations for similar problems, which had been challenging for his mother, both emotionally and financially. 
She repeatedly conveyed to us how much her son meant to her, and that her main priority was to get him home 
soon. At this point, our patient had already started vancomycin and aztreonam for empiric coverage, and we 
recommended switching to cefepime for Pseudomonas coverage. Per the Infectious Disease Fellow, the 
combination of cefepime and vancomycin could act synergistically against MRSA, while covering Pseudomonas. 
Because we were unfamiliar with that clinical reasoning, we took the opportunity to learn more, as this clinical 
presentation is quite common in clinical practice. 
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Clinical Question 
Is there synergistic benefit and reduced bacteremia duration if vancomycin is combined with a cephalosporin or beta lactam to treat 
MRSA bacteremia? 
Research Article 
Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, 
bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527–537. 
https://doi.org/10.1001/jama.2020.0103   
Related Literature 
We searched PubMed using the search terms “MRSA bacteremia treatment vancomycin, β-Lactam,” resulting in 146 items. After 
filtering by “Clinical Trial,” 11 studies remained. Of these 11, three of the studies involved both vancomycin and a beta-lactam 
antibiotic. One article was found through the citation matching function and two additional trials1,2 were similar articles that were 
included. 
The CAMERA2 study was published March 31, 2013 as an open label, randomized control study comparing vancomycin or 
daptomycin, both with and without an anti-staphylococcal beta lactam.3 At the time of the publication of this paper, the study was 
only open for enrollment, with no results. 
Casapao et al. ran a retrospective multicenter cohort study at five academic or community hospitals in the United States on 93 
adults with MRSA bacteremia who were treated with initiation of an intravenous beta lactam within 24 hours of initiating 
vancomycin as compared to standard therapy of intravenous vancomycin. The primary outcome was clinical failure which included 
30-day mortality, persistent bacteremia ≥7 days, bacteremia relapse, or change in antibiotic therapy due to clinical worsening.1 At 
the completion of the trial, combination therapy did not decrease the rate of clinical failure but had expedited bacteremia 
clearance.1 Given the retrospective nature of this article and small sample size, its Strength of Recommendation Taxonomy (SORT) is 
level 2 and was not chosen for appraisal. 
Georges et al. performed a prospective crossover study, written in French, which was carried out on 20 patients with severe 
pneumonia or bacteremia who received either vancomycin 2g per day with cefpirome or standard therapy with vancomycin 2g per 
day. The outcome was evaluated on clinical recovery, duration of ventilation, and ICU stay. Results showed that there was no 
significant difference in clinical outcomes between the two groups, but the bactericidal power in the sera was better in the second 
group.4 This study looked promising, but after searching multiple databases, the whole paper was not available in English. 
After repeating the search, one additional study was added by McCreary et al.2 This retrospective, matched cohort study was done 
on patients with MRSA bacteremia in four US hospitals examining the use of daptomycin and ceftaroline (DAP-CPT) compared to the 
use of the standard of care (SOC). Results showed that DAP-CPT treatment was initiated later in the hospital course as compared to 
the SOC, which resulted in shorter duration of bacteremia in the SOC group. Given the retrospective nature of this study, this study 
was not selected. 
Tong et al. ran an open label, randomized clinical trial on 352 hospitalized patients with MRSA bacteremia at 27 different hospitals in 
four countries from August 2015 to July 2018. Patients were randomized to receive intravenous vancomycin or daptomycin plus an 
anti-staphylococcal beta-lactam or standard therapy with either vancomycin or daptomycin. Primary endpoints of the study were 
90-day composite of mortality, persistent bacteremia at day five, microbiological relapse, and treatment failure. They also had 
secondary outcomes including mortality at days 14, 42, and 90, bacteremia remaining at days two and five, acute kidney injury (AKI), 
relapse, and duration of intravenous antibiotics.5 This study was chosen for appraisal based on the large sample size, recent 
publication, and the direct application to our patient. Per the SORT criteria, this trial has level 2 evidence, given that the study is 
patient oriented, was not blinded, and allocation was not concealed. The overall body of research on this topic meets strength of 
recommendation SORT level B, as currently available evidence is limited. 
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Critical Appraisal 
Tong et al. held their open label, parallel group randomized control clinical trial from August 2015 through July 2018, with follow-up 
completed on October 23. 2018. Hospitalized patients fit trial inclusion criteria with a positive blood culture for MRSA, ability to be 
randomized within 72 hours of first positive blood culture, ≥18 years old, and length of stay at least 7 days after randomization. Our 
patient fit these inclusion criteria. Exclusion criteria included a type 1 hypersensitivity to beta lactams, known pregnancy, expected 
death within 48 hours, polymicrobial bacteremia, treatment limitations precluding antibiotic use, or clinicians refusing patient 
involvement. This last exclusion criterion is probably the largest source of bias in the study design. 
Patient randomization was performed using standard computer software, and a statistician who was uninvolved in the trial made 
the computer-generated randomization codes. Due to cost, neither the patients nor the clinicians were blinded to the therapy. This 
is also a significant source of bias inherent in open label trials. Standard therapy was either vancomycin or daptomycin, compared to 
a beta lactam in combination with vancomycin or daptomycin. All medications were renally dose adjusted. Recommended treatment 
duration was 14-42 days, and if in the trial group, the first seven days with the beta lactam. Any non-antibiotic treatment was left to 
clinician discretion.  Primary outcomes included all-cause mortality, persistent bacteremia at study day five, microbiological relapse 
(defined as a positive blood culture ≥72 hours after a preceding negative culture) and microbiological treatment failure with positive 
sterile site culture for MRSA at least 14 days after randominzation.5 The study was closed by the data safety monitoring board prior 
to the goal of 440 patients enrolled due to the concern of increased incidence of acute kidney injury (AKI) in patients receiving 
combination therapy. Post hoc descriptions included charting creatinine changes from baseline. 
A Mann Whitney U test was used for the continuous outcomes and for the primary endpoint and other categorical measures, the 
absolute difference in proportions were reported with 95% confidence intervals. Twenty-six patients in the combination group did 
not receive at least 75% of the study beta lactam doses and didn’t count in the per protocol population. All data was reported and 
the seven patients who were lost to follow up were considered “treatment failure.” There was no significant improvement of the 
primary endpoint composite of mortality, relapse, or treatment failure when comparing the combination group and the standard 
(35% and 39% respectively), with a difference of −4.2% (95% CI, −14.3% to 6.0%; P = 0.42).5 However, persistent bacteremia on day 
five showed significant decline in patients treated with combination therapy, where 11% were persistently bacteremic in the 
combination group versus 20% in the standard (difference = -8.9%, 95% CI, -16.6 to -1.2%).5 
Treatment length was left to the discretion of the clinician, which could confound any differences seen in results. If patients had 
similar clinical pictures, but one patient had a longer duration of treatment, this would increase the likelihood that the patient with 
longer treatment would have bacteremia clearance. For reference, our patient was scheduled to receive 28 days of therapy due to 
his aortic root dilatation but received eight days of therapy with cefepime. Additionally, these study patients came from four 
different countries and 27 different hospitals, in which antibiotic susceptibilities differ; our local minimum inhibitory concentrations 
(MICs) and susceptibilities likely vary from the countries in this article. Given the incidence of AKI in the combination group with 
flucloxacillin and cloxacillin, more than with cefazolin, further analysis with other cephalosporins is also warranted, as it was 
previously found that anti-staphylococcal penicillins are associated with AKI more than cefazolin (12% vs 3.4% respectively).6 With 
the early study closure, researchers were unable to achieve the primary goal of 440 patients involved in the study, resulting in fewer 
patients for data analysis. Finally, numerous authors released their conflicts of interest and grants/funding received from 
pharmaceutical companies, however no pharmaceutical brand names were used in the trial, mitigating potential funding bias. 
Clinical Application 
After discussion with his mother, she agreed to our combination therapy treatment recommendation. She noted 
that she wanted all interventions for life prolongation except surgical intervention, and her goal for her son was to 
get him back home under her care. Given that his respiratory sample showed both Pseudomonas aeruginosa and 
MRSA, the addition of cefepime was thought to serve dual purposes of treating his Pseudomonal lung infection 
and acting synergistically in his MRSA bacteremia. The possibility of clearing his bacteremia sooner, rooted in 
evidence from Tong et al.'s study, was a major driver in our treatment recommendation for our patient. In 
hindsight, the lack of benefit for the primary endpoint means that the answer to our Clinical Question was “no”, 
there is not synergistic benefit of a cephalosporin administered with vancomycin for MSRA. We used a secondary 
endpoint in a weakly designed clinical trial as the basis of our recommendation. 
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After discussing potential risks such as AKI, and the benefits of hastening bacteremia clearance, his mother was 
amenable to combination therapy. Mr. Edwards was started on combination vancomycin and cefepime on hospital 
day six. He received a total of eight days of combination therapy, and then continued the vancomycin for a total of 
28 days due to his aortic aneurysm. With his first negative blood culture on treatment day four after the initial 
positive culture, we felt he had a positive response to therapy. Although the Tong et al. study showed that 
combination of vancomycin and a beta lactam/cephalosporin did not decrease the primary composite endpoint, 
Mr. Edwards cleared his bacteremia on day four of treatment, consistent with the study's secondary outcome of 
fewer cases of persistent bacteremia on treatment day five in the combination group (11%) versus the standard 
treatment (20%).5  Unfortunately, his many comorbidities persisted, and he did not return to his baseline. Mr. 
Edwards remained intubated throughout his protracted hospital course but showed signs of clinical improvement 
from infection. 
New Knowledge Related to Clinical Decision Science 
With the clearance of Mr. Edwards' MRSA bacteremia on treatment day four, from our perspective this was a successful use of 
combination cefepime and vancomycin that correctly applied existing literature in our patient's context. However, his mother 
wanted a swift return to baseline so he could be discharged home, which was ultimately not met by our treatment, illustrating 
differences in expectations between provider and patient/family. Our optimization of antibiotics as a consulting team, rooted in 
available evidence, met our short-term goals for infection clearance, but we did not completely take into account the broader 
expectations of our patient's mother, and thus in her eyes, our treatment was still unsuccessful.  Additionally, the increased risk of 
AKI with the possibility that this could result in dialysis dependent care would prevent Mr. Edwards’ mother from achieving her 
desired outcome that she clearly expressed to our team. As this outcome reminds us, while meeting medical goals is something to 
strive for, a constant awareness of the patient's goals is required to achieve patient and family satisfaction. As medical professionals, 
our decisions need to be grounded in treating human beings, not diseases. 
Another common topic in Clinical Decision Science is the relationship between specialist consultants and the primary treatment 
team. In this case, reasonable doctors can disagree. Learning how to explain a rationale for making a clinical decision is a skill we all 
need to foster. That would allow higher level discussions between consultants and the primary care doctors who have to integrate 
the evidence into the clinical management plan. 
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